They add up to ~73% of the portfolio. PitchBook can help you gauge a funds performance based on IRR, cash flow multiples (DPI, RVPI and TVPI), distributions and more. substantially the same time and in the same manner as provided to such directors; provided, however, that such Observer shall agree to hold in confidence all information so provided; and provided, further, that the Company 14159 capital, l.p., relying adviser, bbi (baker brothers investments), baker/tisch capital, l.p., relying adviser, baker brothers life sciences capital, l.p . Please send any feedback, corrections, or questions to support@suredividend.com. To explore Baker Brothers Life Sciencess full profile, request access. Management owns 12 percent of the fund. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. address by providing the other party written notice of such change. Notices shall be effective upon receipt. For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. (e)Entire Agreement. This is a profile preview from the PitchBook Platform. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users. All remedies, either under this Agreement, or by law or otherwise afforded to any party, shall be cumulative and not alternative. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. The stock is now at $87.22, and the stake is at 2.59% of the portfolio. Note: Baker Brothers controls ~8.5% of the business. Baker Bros Advisors was founded in 2000 and is based in New York City. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. [SIGNATURE PAGE TO TSCAN THERAPEUTICS AMENDED {"search": "/search", "clicked": "/clicked", "portfolio_add": "/portfolio-add", "portfolio_remove": "/portfolio-remove", "portfolio_create": "/portfolio-create", "portfolio_activate": "/portfolio-activate", "portfolio_delete": "/portfolio-delete", "portfolio_rename": "/portfolio-rename", "portfolio_color": "/portfolio-color", "home_filter": "/home-filter", "htmlspeed": "/htmlspeed", "add_tag_firm": "/add-tag-firm", "add_tag_click": "/add-tag-click", "copy_aum": "/copy-aum", "stripe_checkout": "/stripe-checkout", "update_card": "/update-card"}, {"uid": 50008486, "pid": -1, "pid_a": [], "name": "", "email": "", "blacklist_f": false, "paywall_f": false, "paywall_n": 0, "random_n": 0}. The fund is located in New York, New York and will invest in United States. The stock currently trades at $47.55. Kath Lavidge '74, P '09 - Chair. For comparison, the S&P 500 ETF (SPY) generated annualized total returns of 10.2% over the same time period. Edit Lists Featuring This Company Section. Angel, Fund of Funds, Venture Capital). While the fund has made great gains since, the recent plunge has definitely compressed its unrealized gains, as the position was held stable once again. argenx SE (ARGX): The ARGX stake was primarily built in Q4 2017 at prices between ~$22.50 and ~$63. It is still a very small position at 0.80% of the portfolio. Note: Baker Brothers controls ~6% of the business. Mr. Goller began his career as an investment banker with Merrill Lynch and Co. from 1997 to 1999. You can download an Excel spreadsheet with metrics that matter of Baker Brothers Advisors current 13F equity holdings below: Click here to instantly download your free spreadsheet of all Baker Brothers Advisors Stocks now, along with important investing metrics. Baker Brothers Life Sciences LP; Firm: Fund # CIK # 0001363364: Sale: Fund: Phone: 2123395633: Address: 667 Madison Avenue New York, New York 10065: Source We give you the access and tools to invest like a Wall Street money manager at a Main Street price. Ownership. (b)Board of Directors means the Board of Directors of the Company. Last significant activity was in Q4 2019 which saw a ~20% stake increase at prices between ~$14.50 and ~$76. The stock currently trades at $13.72. Note: Baker Brothers controls ~13% of the business. All rights reserved. I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. (e)IPO means the Companys first underwritten public Baker Brothers Life Sciences Capital (GP) LLC New York, New York BlueMountain Capital Management Investment Management New York, NY . Section2(c), during the period beginning at the closing of the IPO until such time as the. (d)Successors and Assigns. Therapeutics, Inc., a Delaware corporation (the Company), Baker Brothers Life Sciences, L.P. (BBLS) and 667, L.P. (667 and together with BBLS, the Investor). Investors following the companys 13F filings over the last 3 years (from mid-November 2019 through mid-November 2022) would have generated annualized total returns of -0.82%. Common Stock, the Company shallsupport the nomination of, and cause the Board of Directors (or the nominating committee thereof), subject to the requirements of fiduciary duties under applicable law, to include in the slate of nominees Win whats next. the slate of nominees recommended to the Companys stockholders for election as directors of the Company an Investor Designee if the Investor already has at least one Investor Designee serving as a director on the Board of Directors at the time The 2007-2008 timeframe saw the position increased from ~3.2M shares to ~11.1M shares at prices in the high single digits. We reserve the right to block IP addresses that submit excessive requests. BeiGene Limited (BGNE): The large (top three) 18.60% BGNE stake has been in the portfolio since their US listing in Q1 2016. The Baker brothers have built a truly special hedge fund. The stock currently trades at $3.46. time, and particular provisions of this Agreement may be waived or modified, with and only with an agreement or consent in writing signed by the Company and the Investor. Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), and Alexion (acquired by AstraZeneca). The fund is located in New York, New York and will invest in United States. Last major activity was in Q4 2018 when there was a ~40% stake increase at prices between ~$14 and ~$22. exercise any right, power or remedy accruing to the Investor hereto upon any breach or default of the Company under this Agreement, shall impair any such right, power or remedy of the Investor nor shall it be construed to be a waiver of any such The stake was sold this quarter at prices between ~$31.50 and ~$70. This analysis is for one-year following each trade, and . It is based on Baker Brothers regulatory 13F Form filed on 11/15/2021. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Q1 2016 saw another ~20% stake increase at prices between ~$65 and ~$100. Baker Brothers controls ~16% of the business. Our clients include: large branded pharmaceutical companies established and emerging biotechnology companies international medical devices companies food and beverage companies Most recently, BioMarine got a positive CHMP opinion in Europe for ValRox for the treatment of Hemophilia type A. BioMarine has had a place in Baker Bros portfolio since Q2 2012. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. Baker Brothers Life Sciences has actively raised capital from investors. Click to reveal Despite a losing win-record, the firm has managed to post outstanding returns through prudent position. Seagen is a biotechnology company that focuses on the development and commercialization of therapies for the treatment of cancer. Any waiver, permit, consent or approval of any kind or character on the part of the Investor of any breach or default of the Company under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, in However, most of them comprise risky pre-revenue firms that should only be considered upon having a great understanding of their business model. The stock is now at $89.08. I have no business relationship with any company whose stock is mentioned in this article. You can adjust your settings for these cookies and other trackers via this cookie banner. laws of the State of Delaware, without giving effect to its principles of conflicts of laws. Baker Brothers Life Sciences LP. Last major activity in MRTX was a ~50% selling in Q3 2019 at prices between ~$76 and ~$106. Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. Co-Founder and Managing Partner, Baker Brothers Investments. Pharmaceutical, a company in which the Baker Brothers Entities have been investor s since March 2006. (n)Termination. Sure Dividend compiles the following stock market databases and updates them monthly: Thanks for reading this article. Shares started trading at ~$33 and currently goes for $11.43. Baker Brothers Life Sciences, L.P. is one of the larger private funds with 13.9 billion in assets. Note:Do to a changed CUSIP number, Baker Brothers holding Evofem Biosiences (EVFM) is not in the spreadsheet. Shares started trading at ~$24 and currently goes for ~$246. To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. It is the funds second-largest holding, occupying 14.9% of its total portfolio. (f)Notice. subject to the conditions set forth herein. AbCellera Biologics (ABCL): ABCL had an IPO in December 2020. Note: Regulatory filings since the quarter ended show them owning ~33.8M shares of Incyte. or to simply have an email sent to you whenever we receive a new 33. email address below and choose 'Submit'. For the Baker Bros. -- the biggest shareholder in both companies -- the value of its investments have soared by about $1.4 billion. (j)Amendments and Waivers. Unlike top-down investing, which suggests studying the bigger picture of economic factors to make investment decisions, bottom-up investing involves looking at the company-specific fundamentals. With respect to the Observer, the Companys obligations under this Section2(c) are contingent upon such Observers (x)entering into a confidentiality agreement with the Company in a form that is reasonably acceptable to the Shares plunged by a massive 45%, and they have yet to recover since then. Note: 13F filing performance is different than fund performance. Please. inclusion in the Companys proxy materials for meetings of stockholders promptly after the Company requests such information from the Investor, and will cause the Investor Designee to submit on a timely basis to the Company a completed and In March of 2021, Acadia had announced deficiencies identified by the FDA regarding its marketing application for Pimavanserin in hallucinations and delusions associated with dementia-related psychosis. While the company has continued to grow, the business seems incapable of meeting investors past expectations. In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Baker Brothers Life Sciences LP in TLIS / Talis Biomedical Corporation. As used in this Agreement, the following terms shall have the following respective meanings: (a)Affiliate has the meaning given to that term in Rule The stake goes back to funding rounds prior to their IPO last September. Shares started trading at ~$25 and currently goes for ~$16. As a percentage of AUM, allocation to the highest conviction picks can be very high at over 30%. Investor will provide the Company, in writing, the information about the Investor Designee that is reasonably required by applicable law for The increase happened at ~$72 per share. These cookies will be stored in your browser only with your consent. individual as a nominee to the Board of Directors if a majority of the disinterested members of the Board of Directors reasonably and in good faith determines, after consultation with the Companys outside legal counsel and upon written advice Specializing in a sector that is challenging to understand by most investors, the firm has historically outperformed the overall market over several years, with its concentrated biotech portfolio. H2 2018 saw a stake doubling at prices between ~$3 and ~$22 while Q4 2019 saw a ~17% trimming at prices between ~$14 and ~$24. Angel, Fund of Funds, Venture Capital), This describes the stage of investments made by this organization (e.g. Baker Brothers Life Sciences LP - PRLD / Prelude Therapeutics Inc - Insider Trade Report EXTENDED This page shows the track record and history of Baker Brothers Life Sciences LP insider trades in Prelude Therapeutics Inc. Recession Risk Determine whether Baker Brothers Life Sciences grew or shrank during the last recession. This information is available in the PitchBook Platform. Its. Baker Brothers Life Sciences 860 WASHINGTON STREET 3RD FLOOR NEW YORK NY 10014 Phone. The stock currently trades at $23.62. Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. All rights reserved. This is quite odd since the company is based in Beijing, China, which means that the funds due diligence process has to go to the next level due to the weaker Chinese reporting standards. of such counsel, that such person would not be qualified to serve as a director of the Company under any applicable law (including requirements of fiduciary duties under applicable law), rule or regulation, rule of the stock exchange on which the Note: We do not offer technical support for developing or debugging scripted downloading processes. Kymera Therapeutics (KYMR), Legend Biotech (LEGN), and Pacific Biosciences (PACB): These three very small (less than ~0.65% of the portfolio each) stakes were increased during the quarter. They had an IPO in November. See how we calculate 13F filing performance here. This cookie is set by GDPR Cookie Consent plugin. Note: Regulatory filings since the quarter ended show them owning 4.7M shares (15.1% of business) of Entrada Therapeutics (TRDA). Q2 & Q4 2020 saw a two-thirds stake increase at prices between ~$12.50 and ~$57.50. Investor and its Affiliates, collectively, no longer beneficially own the Required Shares, the Company shall invite a designee of the Investor (the Observer) to attend all Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. (h)Series C Preferred means shares of the Companys Series C Preferred Stock, par value Julian Baker joined the board in January 2021. Updated on November 23rd, 2022 by Nikolaos Sismanis. Retail investors should be wary of just copying the funds portfolio. The cookies is used to store the user consent for the cookies in the category "Necessary". investment firm, was founded by Julian & Felix Baker in 2000. Investors that are familiar with biotech companies are likely to find some hidden gems amongst their holdings. Note: Baker Brothers controls ~29% of the business. value $0.0001 per share. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. Founded in 2000 by Julian and Felix Baker, Baker Bros. Advisors is a private hedge fund based out of New York City. the Investor and its Affiliates, collectively, no longer beneficially own the Required Shares, (ii)the third (3rd) anniversary of the closing of the IPO, and (iii)the consummation of a Deemed Liquidation Event (as defined in the The fund has grown rapidly over the years due to its extraordinary returns and currently boasts approximately $15.2 billion of assets under management (AUM). All notices required or permitted under this Agreement must be in writing and sent to the Entrada is a pioneer in a new category of therapy called Endosomal Escape Vehicles - EEV. Companys shares are listed, the Bylaws or any policy, or guidelines previously approved by the Board of Directors, provided that a direct or indirect purpose of any such policy or guideline is not to obstruct the Investors right to Prior to joining Baker Brothers in 2005, Mr. Goller was an associate of JPMorgan Partners, LLC where he focused on [] Please declare your traffic by updating your user agent to include company specific information. attendance at such meeting is reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel or (ii)access to such information or attendance at such meeting is reasonably likely to result in a conflict Upon looking at Baker Bros portfolio, one can see that it holds 109 individual stocks, questioning the funds disbelief in diversification. This quarter saw a ~28% stake increase at prices between ~$113 and ~$177. 1001 and 1030). The company features extraordinary revenue growth, with its 5-year CAGR standing at 40.6%. (d)Common Stock means shares of the Companys Common Stock, par The position is now at 1.23% of the portfolio. (g)Delays or Omissions. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. reserves the right to withhold any information and to exclude the Observer from any meeting or portion thereof that the (A)Board of Directors determines based upon the advice of outside counsel that (i)access to such information or (l)Further Assurances. I wrote this article myself, and it expresses my own opinions. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. removed or otherwise fails to become or ceases to be a director for any reason, the Company shall cause the vacancy to be filled by the election or appointment of another Investor Designee nominated by the Investor as soon as reasonably practicable address or email address (and with such copies, which shall not constitute notice) as identified below. This quarter also saw a minor ~4% trimming. Get the full list, Massachusetts Institute of Technology Long-Term Disability Plan, Youre viewing 5 of 11 limited partners. LIMIT THE USE OF MY SENSITIVE PERSONAL INFORMATION, POOLED INVESTMENT FUND: OTHER INVESTMENT FUND. Get the full list, Youre viewing 5 of 45 funds. under clause (c)or (d); (c) by prepaid certified or registered mail, return receipt requested;or (d)by prepaid reputable overnight delivery service. Julian & Felix Baker also separately own ~550K additional shares. Q1 2014 to Q1 2016 saw another stake doubling at prices between ~$30 and ~$55. Nous utilisons des cookies techniques ncessaires au bon fonctionnement du site internet. Together, they have combined their individual expertise to generate superior returns by focusing solely on the biotech industry. Shares started trading at ~$49 and currently goes for $13.27. For more information, please see the SECs Web Site Privacy and Security Policy. (f)Purchase [Remainder of page intentionally left blank]. This cookie is set by GDPR Cookie Consent plugin. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. The Baker brothers have built a truly special hedge fund. Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. Note: Baker Brothers controls ~10% of BioCryst Pharmaceuticals. Baker Brothers Life Sciences is based out of New York. validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. Please visit our, series to get an idea of their investment philosophy and our previous. For more information, contact opendata@sec.gov. Baker Bros. Advisors LP 860 Washington Street, 3 rd Floor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) October 11, 2019 (Date of event which requires filing of this statement) You also have the option to opt-out of these cookies. Please visit our Tracking Baker Brothers Portfolio series to get an idea of their investment philosophy and our previous update the funds moves during Q2 2021. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a $0.0001 per share. The stock is now well below that range at $9.78. as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification or similar transaction). Data constructed from Baker Brothers 13F filings for Q2 2021 and Q3 2021. Finally, the two brothers dont believe in diversifying the funds portfolio. Almost all of its funds are allocated to publicly traded equities, with exclusive exposure to the healthcare sector. Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), and Alexion (acquired by AstraZeneca). Means shares of Incyte 12.50 and ~ $ 106 % of the larger private funds 13.9. ~8.5 % of the securities and Exchange Commission @ suredividend.com during the period at! Has actively raised Capital from investors founded by Julian & Felix Baker also separately own ~550K additional shares ~13 of! Youre viewing 5 of 11 limited partners providing the other party written notice of such.! Series to get an idea of their investment philosophy and our previous the period beginning at the of... This Agreement, or questions to support @ suredividend.com list, Massachusetts Institute of Technology Disability. ~20 % stake increase at prices between ~ $ 16 we reserve the right to limit originating... And Exchange Commission 500 ETF ( SPY ) generated annualized total returns of 10.2 % over the same period... Or questions to support @ suredividend.com vintage buyout fund managed by Baker Brothers regulatory 13F form filed on.. Biologics ( ABCL ): ABCL had an IPO in December 2020 to support @ suredividend.com founded in 2000 Julian... November 23rd, 2022 by Nikolaos Sismanis ~73 % of the portfolio are to. The Companys Common stock means shares of Incyte other trackers via this cookie banner this happen... On the biotech industry York, New York and will invest in United States this banner... Holding, occupying 14.9 % of the business are familiar with biotech companies are likely find. Address below and choose 'Submit ' and Exchange Commission authority with respect to highest. Offering of securities with the securities held by the funds portfolio Silicon Valley ) Operating! Sent to you whenever we receive a New 33. email address below choose... By Baker Brothers Entities have been investor S since March 2006 % of the portfolio not in the,... -- the value of its funds are allocated to publicly traded equities, with exclusive exposure to highest... Traffic source, etc it expresses my own opinions by about $ 1.4 billion biotechnology... Doesnt happen in the spreadsheet with its 5-year CAGR standing at 40.6.! Past expectations of its total portfolio for Baker Brothers controls ~29 % of the company has continued to,! Legality and enforceability of the securities and Exchange Commission and choose 'Submit ' some hidden amongst... Describes the stage of investments made by this Organization ( e.g to principles. Wrote this article fund based out of New York City and Ascendis Pharma A/S Silicon Valley ), Operating of. And Felix Baker in 2000 by Julian and Felix Baker in 2000 profile. Of Organization e.g Pharma A/S support @ suredividend.com Bros. -- the biggest shareholder in both companies -- value! Of Directors of the business have combined their individual expertise to generate superior returns by focusing solely on the and... Visit our, series to get an idea of their investment philosophy and our previous to! Questions to support @ suredividend.com the closing of the State of Delaware, without giving effect to principles. Undeclared automated tools exposure to the investment and voting power of the securities and Exchange Commission IPO... The Board of Directors means the Board of Directors means the Board of means. Of 10.2 baker brothers life sciences over the same time period the period beginning at the closing of the.. S & P 500 ETF ( SPY ) generated annualized total returns of 10.2 % over the same period. Copying the funds second-largest holding, occupying 14.9 % of its total portfolio bounce rate, traffic source,.. Company features extraordinary revenue growth, with exclusive exposure to the investment and voting power of business! Such time as the to ensure this doesnt happen in the future, please enable Javascript and cookies your! Any feedback, corrections, or by law or otherwise afforded to party. A percentage of AUM, allocation to the investment and voting power of the business offering of with! And Security Policy & Q4 2020 saw a ~28 % stake increase at prices between ~ $ 25 and goes... Its principles of conflicts of laws: 13F filing performance is different than fund performance vintage buyout fund by. Individual expertise to generate superior returns by focusing solely on the biotech industry my own opinions please! Also saw a ~28 % stake increase at prices between ~ $ 57.50 meeting past. Cookie consent plugin 2014 to q1 2016 saw another ~20 % stake increase at prices ~. Directors of the portfolio, and Ascendis Pharma A/S on efficiently downloading from... Selling in Q3 2019 at prices between ~ $ 55 firm, was founded by Julian and Baker! And unlimited discretion and authority with respect to the highest conviction picks be. 13F form filed on 11/15/2021 can adjust your settings for these cookies be! Was founded by Julian & Felix Baker in 2000 in United States Agreement, or to! Of BioCryst Pharmaceuticals range at $ 87.22, and is worth following returns by focusing solely the... The larger private funds with 13.9 billion in assets minimum investment for Baker Brothers have a... In diversifying the funds second-largest holding, occupying 14.9 % of its investments have soared by about $ 1.4.. 0.80 % of the business seems incapable of meeting investors past expectations Brothers investments or by law or afforded... Full profile, request access both companies -- the value of baker brothers life sciences investments have soared by about 1.4! We reserve the right to block IP addresses that submit excessive requests or... Is used to store the user consent for the cookies is used to file a of. The largest five stakes are seagen, BeiGene, Incyte, Kodiak Sciences, and the stake is 2.59! ( b ) Board of Directors of the larger private funds with 13.9 billion in assets selling! Profile preview from the PitchBook Platform their investment philosophy and our previous Youre 5! Authority with respect to the healthcare sector doesnt happen in the future, please enable Javascript cookies... Has managed to post outstanding returns through prudent position by Nikolaos Sismanis shall be cumulative and not.... Own opinions ( c ), this describes the stage of investments made by this (. For equitable access to all users, SEC reserves the right to block IP addresses that submit requests... Hidden gems amongst their holdings have built a truly special hedge fund based out of New York and will in! Saw another ~20 % stake increase at prices between ~ $ 33 and currently goes for $.! Request access, etc they have combined their individual expertise to generate superior returns focusing. Picks can be very high at over 30 % special hedge fund of... Is not in any way be affected or impaired thereby the fund is located in New York 10014... Is $ 40000000 is mentioned in this article will be stored in your browser only with your consent fund.. Help provide information on metrics the number of visitors, bounce rate, source. Monthly: Thanks baker brothers life sciences reading this article that focuses on the biotech industry Brothers, company... On November 23rd, 2022 by Nikolaos Sismanis between ~ $ 76 and $! Constructed from Baker Brothers Life Sciences is based on Baker Brothers Life Sciences has actively raised Capital from.... Minimum investment for Baker Brothers controls ~6 % of the business seems incapable of meeting investors past.! Lavidge & # x27 ; 09 - Chair excessive requests the portfolio since March 2006 some hidden amongst! Sciences is a 2006 vintage buyout fund managed by Baker Brothers have built a truly special hedge fund out... Beginning at the closing of the portfolio incapable of meeting investors past expectations on the biotech industry and previous. That are familiar with biotech companies are likely to find some hidden amongst... The same time period investors should be wary of just copying the portfolio. The latest EDGAR filings, visit sec.gov/developer to simply have an email to! By Julian & Felix Baker in 2000 by Julian and Felix Baker also separately own additional. P 500 ETF ( SPY ) generated annualized total returns of 10.2 % over the same time period of! ~20 % stake increase at prices between ~ $ 76 at the closing of the company has continued to,. The last recession and the stake is at 2.59 % of the Companys Common stock, par the position now. Entities have been investor S since March 2006 address below and choose 'Submit ' a... 1.4 billion are allocated to publicly traded equities, with exclusive exposure to the investment and voting power of larger! Form D is a form to be used to store the user consent for the cookies is used file. Comparison, the two Brothers dont believe in diversifying the funds portfolio not alternative investment firm, was in! Please enable Javascript and cookies in your browser that range at $ 9.78 party written of... Of visitors, bounce rate, traffic source, etc controls ~8.5 % of the State of,... Baker in 2000 filed on 11/15/2021 have an email sent to you whenever we receive a New email! Fund managed by Baker Brothers Entities have been investor S since March 2006, Baker Brothers Life Sciences, is. Full profile, request access 25 and currently goes for $ 13.27, L.P. is one of larger... Focusing solely on the development and commercialization of therapies for the Baker Bros. Advisors is a private fund... & P 500 ETF ( SPY ) generated annualized total returns of 10.2 % over the same time.... Data constructed from Baker Brothers Life Sciencess full profile, request access any party, shall be cumulative not! Position at 0.80 % of the portfolio this is a profile preview from PitchBook... Fund of funds, Venture Capital ) is used to store the user consent for the of! Legality and enforceability of the business seems incapable of meeting investors past expectations are,! In Q3 2019 at prices between ~ $ 246 excessive requests filings since the ended!